Tags

Type your tag names separated by a space and hit enter

Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation.
Transfusion. 2004 Aug; 44(8):1179-85.T

Abstract

BACKGROUND

To evaluate the risk of human parvovirus B19 (B19) transmission in recombinant antihemophilic factor, the seroprevalence among 798 two- to seven-year-old boys with hemophilia was compared. Also, data collected on joints were used to assess relations between B19 serostatus and joint range-of-motion (ROM) limitation.

STUDY DESIGN AND METHODS

Staff at US hemophilia treatment centers collected data on product exposures and ROM of 10 joints and provided blood specimens as part of blood safety surveillance. Blood was tested for immunoglobulin G anti-B19. Associations between B19 seropositivity and treatment products and joint ROM limitations were examined in multivariate analyses.

RESULTS

Compared to children who received no product, the odds of B19 seropositivity were 0.8 (p = 0.5), 1.9 (p = 0.05), and 7.6 (p < 0.001) for those children who received recombinant antihemophilic factor only, both recombinant antihemophilic factor and plasma-derived factor, and plasma-derived factor only, respectively. Children who were anti-B19 positive had an average 8 degrees less overall ROM (p = 0.002) than those who were B19 antibody negative after adjustment for other risk factors.

CONCLUSION

The risk of B19 transmission by recombinant antihemophilic factor is low. Previous B19 infection is associated with ROM limitations in very young male patients with hemophilia. Virus inactivation techniques effective against B19 and other nonenveloped viruses are needed.

Authors+Show Affiliations

Division of Hereditary Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia 30303, USA. msoucie@cdc.govNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15265122

Citation

Soucie, J Michael, et al. "Human Parvovirus B19 in Young Male Patients With Hemophilia A: Associations With Treatment Product Exposure and Joint Range-of-motion Limitation." Transfusion, vol. 44, no. 8, 2004, pp. 1179-85.
Soucie JM, Siwak EB, Hooper WC, et al. Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation. Transfusion. 2004;44(8):1179-85.
Soucie, J. M., Siwak, E. B., Hooper, W. C., Evatt, B. L., & Hollinger, F. B. (2004). Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation. Transfusion, 44(8), 1179-85.
Soucie JM, et al. Human Parvovirus B19 in Young Male Patients With Hemophilia A: Associations With Treatment Product Exposure and Joint Range-of-motion Limitation. Transfusion. 2004;44(8):1179-85. PubMed PMID: 15265122.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation. AU - Soucie,J Michael, AU - Siwak,Edward B, AU - Hooper,W Craig, AU - Evatt,Bruce L, AU - Hollinger,F Blaine, AU - ,, PY - 2004/7/22/pubmed PY - 2004/8/20/medline PY - 2004/7/22/entrez SP - 1179 EP - 85 JF - Transfusion JO - Transfusion VL - 44 IS - 8 N2 - BACKGROUND: To evaluate the risk of human parvovirus B19 (B19) transmission in recombinant antihemophilic factor, the seroprevalence among 798 two- to seven-year-old boys with hemophilia was compared. Also, data collected on joints were used to assess relations between B19 serostatus and joint range-of-motion (ROM) limitation. STUDY DESIGN AND METHODS: Staff at US hemophilia treatment centers collected data on product exposures and ROM of 10 joints and provided blood specimens as part of blood safety surveillance. Blood was tested for immunoglobulin G anti-B19. Associations between B19 seropositivity and treatment products and joint ROM limitations were examined in multivariate analyses. RESULTS: Compared to children who received no product, the odds of B19 seropositivity were 0.8 (p = 0.5), 1.9 (p = 0.05), and 7.6 (p < 0.001) for those children who received recombinant antihemophilic factor only, both recombinant antihemophilic factor and plasma-derived factor, and plasma-derived factor only, respectively. Children who were anti-B19 positive had an average 8 degrees less overall ROM (p = 0.002) than those who were B19 antibody negative after adjustment for other risk factors. CONCLUSION: The risk of B19 transmission by recombinant antihemophilic factor is low. Previous B19 infection is associated with ROM limitations in very young male patients with hemophilia. Virus inactivation techniques effective against B19 and other nonenveloped viruses are needed. SN - 0041-1132 UR - https://www.unboundmedicine.com/medline/citation/15265122/Human_parvovirus_B19_in_young_male_patients_with_hemophilia_A:_associations_with_treatment_product_exposure_and_joint_range_of_motion_limitation_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=0041-1132&amp;date=2004&amp;volume=44&amp;issue=8&amp;spage=1179 DB - PRIME DP - Unbound Medicine ER -